Table 1

Characteristics of matched cases with JIA-U and control patients with JIA

JIA-U (n=46)JIA (n=46)P value
Age at JIA diagnosis in years, median (IQR)2.5 (1.9–4.5)2.6 (2.0–5.1)0.58
Age at uveitis diagnosis in years, median (IQR)5.1 (4.0–6.4)
Female, n (%)37 (80.4)40 (87.0)0.57
Disease duration in years*, median (IQR)1.9 (0.6–3.0)1.9 (0.6–2.9)0.92
Active joint count at JIA diagnosis, median (IQR)3 (1–4)
n=22
2 (1–3)
n=24
0.70
JIA subtype, n (%)*
 Oligoarthritis39 (84.8)39 (84.8)
 RF-polyarthritis7 (15.2)7 (15.2)
Serum markers
 ANA positive, n (%)38 (82.6)38 (82.6)*
 HLA-B27 positive, n (%)2 (20.0)
n=10
0 (0.0)
n=8
0.58
ESR (mm/hour) at JIA diagnosis, median (IQR)40 (25–50)
n=40
30 (18–47)
n=39
0.11
  • *Time from JIA diagnosis to uveitis diagnosis for cases with JIA-U, and matched durations for control patients with JIA.

  • ANA, antinuclear antibodies; ESR, erythrocyte sedimentation rate; HLA, human leucocyte antigen; JIA, juvenile idiopathic arthritis; JIA-U, JIA-associated uveitis; RF, rheumatoid factor.